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The field of oral anticoagulation has evolved with the arrival of non-vitamin K antagonist oral anticoagulants (NOACs) including
an anti-IIa agent (dabigatran etexilate) and anti-Xa agents (rivaroxaban and apixaban). The main specificities of these drugs
are predictable pharmacokinetics and pharmacodynamics but special attention should be paid in the elderly, in case of renal
dysfunction and in case of emergency. In addition, their perioperative management is challenging, especially with the absence
of specific antidotes. Effectively, periods of interruption before surgery or invasive procedures depend on half-life and keeping
a permanent balance between bleeding and thromboembolic risks. In addition, few data regarding the link between plasma
concentrations and their effects are provided. Routine laboratory tests are altered by NOACs and quantitative measurements are
not widely performed. This paper provides a review on the management of NOACs in the perioperative setting, including the
estimation of the bleeding and thrombotic risk, the periods of interruption, the indication of heparin bridging, the usefulness of
laboratory tests before surgery or invasive procedure, and the time of resuming. Most data are based on expert’s opinions.
1. Introduction
Three non-vitamin K antagonist oral anticoagulants
(NOACs) [1] are already widely used in the clinical setting:
rivaroxaban and apixaban, two direct factor Xa (FXa) inhi-
bitors, and dabigatran etexilate (DE)—the prodrug of dabiga-
tran, a direct thrombin inhibitor. Both of these drugs will
progressively tend to replace vitamin K antagonists (VKAs)
in most of their indications. NOACs indications vary among
countries. They are licensed for long-term prevention of
thromboembolic events in nonvalvular atrial fibrillation
(NVAF), for thromboprophylaxis of venous thromboembol-
ism (VTE) including deep venous thromboembolism (DVT)
and pulmonary embolism (PE) after hip and knee arthro-
plasty, and for the treatment and secondary prophylaxis of
VTE. Rivaroxaban is also approved in Europe for secondary
prevention of atherothrombotic events after acute coronary
syndrome (ACS) with elevated cardiac biomarkers [2–7].
Advantages of NOACs include rapid onset and offset
of action and relatively predictable anticoagulation effects
[8]. In most patients, routine laboratory monitoring of the
anticoagulant effect is not required but the assessment of the
estimated renal clearance is necessary [9]. In some cases (e.g.,
emergencies, bleeding, overdose, and trauma), the anticoag-
ulation status and the alteration of standard laboratory data
must be known [10, 11]. An increasing number of patients
on long-term treatment with NOACs are encountered in the
perioperative setting and it is essential for physicians to be
aware of the pharmacological properties of these drugs. The
management of those patients requires an involvement of
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all participating teams (general practitioners, surgeons, anes-
thesiologists, and other healthcare professionals involved in
invasive procedures). Their cessation is indisputable in most
elective procedure, but the risk between thrombosis and
bleeding should be balanced [12]. In some settings, the
therapeutic window is bridged by low molecular weight hep-
arin (LMWH) or unfractionated heparin (UFH) to prevent
thromboembolic risk [13, 14]. No specific antidote is currently
available in case of bleeding so clinicians have to deal with
rescue treatments [15].The optimal time forNOAC’s resump-
tion depends mainly on the postoperative risk of bleeding
[16].
This paper aims at providing a review on themanagement
of NOACs in the perioperative setting in accordance with the
current literature.This includes the estimation of the bleeding
and thrombotic risk of each patient, the period of NOAC’s
interruption before an invasive procedure, the conditions for
heparin bridging during this interruption, the usefulness of
common and specific laboratory tests to assess the remaining
anticoagulant effect preoperatively, and the time of NOAC’s
resumption prerequisites for the perioperative management
of NOACs. The literature search was performed in PubMed
using the following keywords: perioperative, anticoagulant,
dabigatran, rivaroxaban, and apixaban. Overall inclusion of
papers was limited to studies published until May 30, 2014.
2. Indications and Posology of NOACs
Three molecules are currently available in the clinical setting:
dabigatran etexilate (Pradaxa, Boehringer-IngelheimPharma
GmBH, Ingelheim am Rhein, Germany): 75mg, 110mg, and
220mg capsules, rivaroxaban (Xarelto, Johnson and John-
son/Bayer HealthCare AG, Leverkusen, Germany): 2.5mg,
10mg, 15mg, and 20mg tablets, and apixaban (Eliquis, Bristol
Myers Squibb/Pfizer, Bristol Myers Squibb House, Uxbridge,
United Kingdom): 2.5mg and 5mg tablets.
Table 1 summarizes the approved indications by the Food
and Drug Administration and the European Commission,
the posology, and the dose adaptation of the differentNOACs.
Table 2 summarizes the main studies leading to the
approved indications of NOACs [17–27].
3. Clinician Oriented Overview of
Pharmacokinetic Properties of NOACs
3.1. Dabigatran Etexilate (Pradaxa, Boehringer-Ingelheim
Pharma GmBH, Ingelheim am Rhein, Germany): 75mg,
110mg, and 220mg Capsules. Dabigatran etexilate is the
prodrug of dabigatran, a selective and reversible oral direct
thrombin inhibitor. The plasma peak after ingestion is at 1.5–
3.0 hours and the plasma trough level is 11–14 hours after
ingestion in healthy volunteers [28]. Bioavailability varies
from 3 to 7% depending on the pH encountered in the
microenvironment of the gastrointestinal tract. Dabigatran is
35%bound to plasma proteins, allowing theoretically its elim-
ination by hemodialysis. Eighty percent of the drug is directly
eliminated in the urine, explaining that, in the setting of
renal insufficiency, the anticoagulant effect accumulates. Its
elimination half-life rises to 18–24 hours in patients with
significantly impaired renal function compared to healthy
elderly subjects [29]. Creatinine clearance (CrCl) estimation
based on the Cockroft and Gault formula [30, 31] is recom-
mended in elderly patients to calculate doses and avoid over-
medication [9]. Twenty percent is conjugated as glucuronides
by hepatic metabolism. Dabigatran etexilate is contraindi-
cated in case of severe renal impairment (CrCl < 30mL/min)
in Europe while a lower dose is proposed in North
America for CrCl between 30 and 15mL/min [32]. Hepatic
impairment or liver disease with expected impact on survival
is also a contraindication [33, 34].
3.2. Rivaroxaban. Rivaroxaban is a selective and reversible
oral direct FXa inhibitor.The plasma peak after ingestion is at
2–4 hours and the half-life elimination is 5–9 hours in healthy
volunteers and 11–13 hours in the elderly [28]. Bioavailability
is between 80 and 100% for 10mg and around 66% for 15 or
20mg under fasting conditions. Rivaroxaban is bound to
plasma proteins in more than 90%, making hemodialysis
ineffective to eliminate this drug. About one-third (36%) of
the dose is eliminated by renal pathway as unchanged active
drug, and the approximately remaining two-thirds of the dose
is subject to metabolic degradation. Metabolites are elimi-
nated equally via renal pathway and via hepatobiliary route in
the feces [35]. Clearance is mildly influenced by renal func-
tion [36]. Rivaroxaban is not recommended in severe renal
impairment (ClCr < 15mL/min) [32].
3.3. Apixaban. Apixaban is a selective and reversible oral
direct FXa inhibitor. The plasma peak after ingestion is at 2-
3 hours and the half-life elimination is 8–15 hours in healthy
volunteers [28]. Apixaban is 87% bound to plasma proteins.
Bioavailability is around 50%. Apixaban is eliminated via
multiple pathways: predominantly via the fecal route (56%)
and 25–29% via renal excretion [37]. Apixaban is not recom-
mended in severe renal impairment (ClCr < 15mL/min) [32].
Table 3 proposes an overview of the main pharmacoki-
netic properties of direct oral anticoagulants.
4. Drugs Interactions
Twomechanisms aremainly involved inNOACs’metabolism
and elimination: the efflux operated by P-glycoprotein (P-
gp) and the CYP450 isoform CYP3A4. Dabigatran etexilate
is metabolized in dabigatran in the plasma and liver via
CYP450-independent mechanisms [38], but DE acts as a
substrate for P-gp. Therefore, strong inhibitors or inducers
of P-gp may alter the absorption of DE [39]. Rivaroxaban
and apixaban are metabolized by CYP3A4/5 and are both
substrates for P-gp.Thus, drugs that strongly inhibit or induce
CYP3A4 or P-gp or both influence the pharmacokinetic (PK)
profile of these NOACs [39, 40].
5. Perioperative Management of NOACs
As illustrated in the RE-LY (randomized evaluation of long-
term anticoagulation therapy) study [41], 25% of the patients
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Table 3: Overview of main pharmacokinetic properties of NOACs.
Dabigatran etexilate Rivaroxaban Apixaban
Plasma peak (hours) 1.5–3.0 2.0–4.0 3.0-4.0
Elimination half-life (hours)
11–14: healthy volunteers
18–24: significantly impaired
renal function
5–9: healthy volunteers
11–13: elderly 8–15: healthy volunteers
Protein binding (%) 35% >90% 87%
Elimination (%) 80% active renal20% faecal
33% non-active renal
66% metabolized: (metabolism:
50% renal and other half by
hepatobiliary route)
Multiples pathways:
25%–29% renal
56% by faecal route
Bioavailability 3–7%PH sensitive
80–100% 10mg
66%: 15–20mg under fasting
conditions
±50%
Table 4: CHA2DS2-VASc Score.
Acronym CHA2DS2-Vasc Score Points
C Congestive heart failure 1
H Hypertension 1
A2 Age ≥ 75 years 2
D Diabetes mellitus 1
S2 Stroke, transient attack, or thromboembolism 2
V Vascular disease (prior myocardial infarction, peripheral arterial disease, aortic plaque) 1
A Age 65–74 years 1
Sc Sex category: female 1
on anticoagulant therapy required a transitory cessation
during the two years of follow-up while, in the ROCKET-AF
(rivaroxaban once daily oral, direct factor Xa inhibition com-
pared with vitamin K antagonism for prevention of stroke
and embolism in atrial fibrillation) study [42], 33% of the
patients experienced a temporary interruption of anticoagu-
lant therapy. Forty percent of these interruptions were before
surgical or invasive procedure.
In the perioperative context, the balance between throm-
bosis (in case of anticoagulation interruption) and bleeding
(in case of anticoagulation continuation) should be assessed
for each patient [43].
5.1. TheThromboembolic Risk
5.1.1. For the Arterial Side. In developed countries, atrial fib-
rillation (AF) affects about 1.5 to 2% of the population. This
arrhythmia is associated with a 5-fold increased risk of stroke
(AF is associated with 15–20% of all strokes [44]), a 3-fold
increased incidence in congestive heart failure, and a higher
mortality [45]. Scores that assess thrombotic risk in the peri-
operative setting are not well established, whereas in certain
chronic conditions risks like AF, stratification scores help in
decision making when the risk of thrombosis and bleeding
must be weighted [46, 47]. The most widely used score is the
CHADS
2
score (congestive heart failure, hypertension, age >
75 years, diabetes, and prior stroke/transient ischemic attack).
It is validated for predicting AF-related thromboembolic risk
events and helps for the optimal selection of VKAs and
NOACs therapies [46, 47]. Since 2010, the CHA
2
DS
2
-VASc
score (including cardiovascular disease, atherosclerotic dis-
ease, and female sex as additional risk factors) (Table 4)
improves the predictive value for thromboembolism. Only a
small proportion of patients belong to the low risk and inter-
mediate risk categories [46, 48]. Patients with CHA
2
DS
2
-
VASc score ≥ 2 are considered at high risk of thrombosis [46].
The ARISTOTLE (apixaban for reduction in stroke and
other thromboembolic events in atrial fibrillation) trial shows
a superiority of apixaban over warfarin in terms of stroke or
systemic embolism prevention [20, 49] whatever the assess-
ment of stroke risks by CHADS
2
and CHA
2
DS
2
-VASc [50].
Actually, the assessment of periprocedural thrombotic risk is
extrapolated from the risk outside the periprocedural period
[12].
5.1.2. For the Venous Side. Patients with venous thromboem-
bolism are at high risks of recurrent thrombosis, thrombus
propagation, and embolization until 3 months after diagnosis
and initiation of anticoagulation therapy [51]. The risk of
recurrence is conditioned by the underlying cause. It decre-
ases if the etiology is provoked (e.g., trauma, fractures, and
pregnancy), but if the underlying cause is idiopathic, the risk
of recurrence is higher [52].
5.2.The Bleeding Risk. The bleeding risk is multifactorial and
its assessment needs to consider patient-specific and proce-
dure-specific variables [53].
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Table 5: HAS-BLED score.
HAS-Bled Score Risk Factor Points
H Hypertension (uncontrolled, systolic blood pressure >160mmHg) 1
A Abnormal renal function or liver function 1 or 2 (each 1)
S Stroke 1
B Bleeding history or predisposition to bleeding (e.g., bleeding diathesis, anemia) 1
L Labile INR 1
E Elderly (age > 65 years) 1
D Drug (antiplatelet, nonsteroı¨dal anti-inflammatory drugs) or alcohol abuse 1 or 2 (each 1)
5.2.1. Patient-Specific Variables
For the Arterial Side. HAS-BLED score is used to assess
1-year risk of major bleeding in patients with AF under
VKAs [54] (Table 5). Other scores such as ATRIA [55] and
HEMORR
2
HAGES [56] scores are also used [57]. All these
scores offer a modest predictive performance of the estima-
tion of the bleeding risk in NOACs treated patients with AF.
However, HAS-BLED and HEMORR
2
HAGES scores are
superior in terms of clinically relevant bleeding for patients
on NOACs [58]. Nevertheless, a second analysis of the ARIS-
TOTLE trial shows less bleeding under apixaban compared
with warfarin, independently of the HAS-BLED score [50].
For the Venous Side. The RIETE score (Registro Informati-
zado de Enfermedad Tromboembo´lica) assesses the risk of
fatal bleeding in VTE patients and seems better in predicting
gastrointestinal than intracranial fatal bleeding [59].
5.2.2. Procedure-Specific Variables. There is little data avail-
able to identify the risk of blood loss related to the invasive
procedure or surgery [60], except for cardiac surgery [61].The
estimation of bleeding risk for surgery/invasive procedure
remains controversial for certain procedures andhas low level
of evidence [13]. Furthermore, there is a high intercenter
variability in red cell blood loss for the main procedure,
mainly reflecting differences in surgical techniques. Similarly,
classifications into different surgery bleeding risks according
to the severity of trauma and the risk of periprocedural
bleeding [12, 60, 62–65] are not always easy to use in
daily practice. Therefore, it is recommended to develop an
institutional guideline and a hospital-wide policy concerning
perioperative anticoagulation management in different pro-
cedures [63].
5.3. Interval between Last Dose and Invasive Procedure or
Surgery. The interval between the last dose and the invasive
procedure or surgery depends on the bleeding risk of the
procedure and the drug half-life (Table 3).
5.3.1. The Invasive Procedure or Surgery. Some procedures
defined as minimal procedures with little tissue trauma are at
low risk for bleeding [14, 63, 66] and can be achieved
without interruption ofNOACs (e.g., superficial skin and oral
mucosal surgery, wound revisions, nonextraction dental
treatment, or cataract surgery). Gastrointestinal endoscopic
biopsy without cessation of DE seems to be safe according to
current Japanese guidelines [67]. It is recommended to
perform the procedure at the trough drug concentration (12
or 24 hours after the last intake) [13, 63, 68].
5.3.2. Drug Metabolism and Elimination. The percentage of
drug eliminated after 2, 3, 4, and 5 half-lives is 75%, 87.5%,
93.8%, and 96.9%, respectively [69]. Dabigatran etexilate,
rivaroxaban, and apixaban have different drug metabolic
and elimination pathways (Table 3). Creatinine clearance
(CrCl) must be assessed by the Cockroft and Gault method.
Estimation of renal function byModification of Diet in Renal
Disease Equation 4 (MDRD 4) leads to an overestimation of
the renal function at lower levels.Thus, many elderly patients
with AF would either become incorrectly eligible for NOACs
or would receive a too high dose, which may explain the
serious incidences of bleeding reported [9, 30].
Some specific populations have an increased half-life of
NOACs’ elimination and need therefore special attention.
This concerns patients with renal or hepatic impairment, par-
ticularly the elderly with fluctuating renal function, diuretic
use, hypovolemia, liver chronic infections, liver cirrhosis,
alcohol abuse, obstructed bile flow, hepatorenal syndrome,
and associated coagulopathy. Assessing both renal and liver
function must be done preoperatively for every patient on
NOACs. The three agents can be used in mild hepatic
impairment (Child-Pugh A), while DE and apixaban are
allowed inmoderate hepatic impairment (Child-Pugh B), but
not in severe hepatic impairment (Child-Pugh C) [70].
It is also important to check preoperatively any off-label
use or misuse of these NOACs, including the concomitant
medications (verapamil, dronedarone, ketoconazole, amio-
darone, tacrolimus, etc.), older ages, and extreme body
weights. All of these groups should probably require a longer
interval of NOACs’ arrest, and a measurement of the anti-
coagulant residual activity should be considered before an
invasive procedure.
Several interval schemes based on expert’s opinions
are proposed taking into account NOACs’ pharmacokinet-
ics, patient, and/or type of invasive procedure or surgery
(Table 6).
The “Groupe d’Inte´reˆt en He´mostase Pe´riope´ratoire”
(GIHP) proposes a unique scheme: 1 day of interruption in
case of low risk bleeding surgery or procedure and 5 for
other procedures, whatever the molecule, renal function, and
concomitant medications [13]. The duration of stopping is
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proposed empirically to ensure no residual anticoagulant
effect in the absence of a validated antidote.
Except for minimal procedures which can be achieved
without stopping NOACs, other experts or expert groups
propose a window without any NOAC, according to the CrCl
and/or the type of surgery. An interval of at least 48 hours
(about 3 half-lives) should be maintained for a patient with
a CrCl above 50mL/min to perform surgery or invasive pro-
cedure, whatever the molecule. The free interval is increased
to at least 4 days for patients on DE with CrCl between 30
and 50mL/min or for patients on rivaroxaban/apixaban with
a CrCl between 15 and 30mL/min (Table 6). Further large
prospective studies are needed to confirm the safety of these
perioperative procedures.
5.4. To Bridge or Not to Bridge during the Perioperative
Interruption. For patients on VKA, the procedure is well
established [12, 60]. Guidelines recommend to bridge patients
at high risk for thromboembolism (mechanical heart valve,
AF, or VTE) with LMWH. For patients at low risk for throm-
boembolism, they suggest no bridging in case of stopping
[60, 71]. Patients classified as being at high risk have more
than 10% annual risk for thromboembolism while this risk is
reduced to less than 5% for those classified as being at low risk
[60].
For VKAs, Siegal et al. [71] as well as Feng et al. [72]
showed an increased risk of bleeding with similar thrombotic
risk among patients who underwent periprocedural bridging
therapy with heparin bridging. Recently, Omran et al. [73]
have validated a HAS-BLED score ≥ 3 as the most predictive
variable for hemorrhage for patients who had heparin bridg-
ing during a perioperative interruption of VKAs before an
elective invasive procedure.
Expert’s opinions recommend no heparin bridging for
NOACs [62, 63, 74], except the GIHP [13]. The last group
proposes to stopNOACs 5 days before a surgerywithmedium
or high risk of bleeding, to ensure a complete elimination of
the drug in all patients. And if the patient is at high throm-
boembolic risk (e.g., AFwith a history of stroke), they suggest
bridging with LMWH or UFH.
Beyer-Westendorf et al. [14] had recently presented the
first prospective data from a national registry that supported
the concept of short-term interruption without heparin
bridging.
They concluded that if a surgery or an invasive procedure
requires a NOAC’s arrest, most patients can safely interrupt
NOACs for a short period without heparin bridging. In case
of heparin bridging therapy, the rate of cardiovascular events
is not reduced. There is a significantly higher rate of bleeding
complications due to heparin bridging or major procedures.
However, patients at cardiovascular risk undergoing major
procedures may benefit from heparin bridging because their
outcome in terms of cardiovascular risk is increased and
because, in this particular setting, heparin bridging is not an
independent factor for bleeding risk.
Those data do not support a systematic bridging therapy
but highlight its probable benefit in patients at cardiovascular
risk undergoing high risk surgery. Table 7 shows categories of
procedures defined by the severity of tissue trauma and the
risk for periprocedural bleeding [14].
During the ROCKET-AF trial, patients who required
temporary interruption of anticoagulant therapy for surgery
and invasive procedure were bridged only in 6% of the cases,
predominantly by LMWH. The rate of major bleeding was
similar in bridged and nonbridged patients. The incidence
of bleeding (major and nonmajor clinically relevant bleed-
ing according to International Society on Thrombosis and
Hemostasis definitions [75]) was higher in case of bridging
therapy, while stroke and systemic embolism were similar in
both groups [42]. The study suffers several biases such as the
use of bridging therapy in a nonrandomized way and the too
low number of events.
Devices implants in most of Canadian centers are per-
formed with NOAC interruption without LMWH bridging
[76]. Again, this study demonstrates the necessity of an indi-
vidual assessment of each patient, on a case-by-case basis
[77].
Thus, there is no universal strategy for periprocedural
management of NOACs, but a stepwise approach can be
considered. Some prerequisites are essential to allow peripro-
cedural decision (Table 8).
The decision about perioperative NOACs management
should be written in the medical record.
5.5. A Particular Case: Anesthesia Procedures
5.5.1. Neuraxial Anesthesia. For patients without thrombotic
risk (assessed by CHA
2
D
2
-VASc score), Benzon et al. [78]
recommend 5 half-life intervals between NOAC’s discontin-
uation and a neuraxial puncture (with or without epidural
catheter placement). For patients with high risk of stroke or
VTE, this interval can be shortened to 2 or 3 half-lives, or
it can stay at 5 half-lives if LMWH bridging is associated.
Llau and Ferrandis [79] provided recommendations based on
NOAC’s pharmacokinetics in the setting of thromboprophy-
laxis. For spinal anesthesia, if the puncture is atraumatic, the
first dose of DE can be administrated 1–4 hours after the end
of surgery and after 6–8 hours for rivaroxaban. If the
puncture is traumatic or hemorrhagic, the first dose of DE or
rivaroxaban is delayed by 24 hours. For epidural anesthesia,
DE cannot be administrated if a permanent catheter is
inserted. For rivaroxaban, the first dose after epidural anes-
thesia is administered 6–10 hours after the end of surgery. An
interval of 18 hours is recommended before the removal of the
epidural catheter (22–26 hours for elderly patients) and at
least 4 hours after removal. The European Society of Anaes-
thesiology (ESA) [80] recommends extreme caution when
using neuraxial blockade in the presence of rivaroxaban/
apixaban. For dabigatran, themanufacturer advises against its
use in the presence of neuraxial blockade. Because of a poten-
tial risk of retroperitoneal hematoma in lumbar plexus and
paravertebral blocks, ESA recommends the same guidelines
for these two peripheral nerve blocks as for neuraxial block-
ades [78, 80].
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Table 7: Categories of procedures according to the severity of tissue
trauma and the risk for peri-procedural bleeding.
Minor procedures with little tissue trauma
Superficial skin and oral mucosal surgery, skin biopsies
Wound revisions
Non-extraction dental treatment
Minor procedures with little tissue trauma, but relevant bleeding
risk
Transluminal cardiac, arterial, and venous interventions
Pacemaker-related surgery
Pleura and ascites punctures
Cataract surgery
Arthroscopy, endoscopy, laparoscopy
Organ biopsies
Dental extraction
Hernia repair
Intramuscular and paravertebral injections
Major procedures with relevant tissue trauma and high bleeding
risk
Open pelvic, abdominal and thoracic surgery
Brain surgery
Major orthopedic and trauma surgery
Vascular surgery
5.5.2. Other Peripheral Nerve Blocks. ESA does not routinely
apply the same guidelines as for neuraxial blockades [81], but
the American Society of Regional Anesthesia (ASRA) does
[78].
5.6. A Particular Case: Atrial Fibrillation Ablation. Uninter-
rupted warfarin therapy with therapeutic anticoagulation has
been shown to be associatedwith lower risk of periprocedural
thromboembolic events after AF ablation and is increasingly
being accepted as the preferred anticoagulation strategy [82].
However, increasingly more patients are being treated with
NOACs, thereby complicating the periprocedural anticoagu-
lation management.
For dabigatran, there is no consensus regarding the man-
agement of patients taking dabigatran who are referred for
AF ablation. The results depend on the period of dabigatran
interruption. Nearly uninterrupted anticoagulation (holding
themorning dose), which theoretically has a better protection
from periprocedural thromboembolism, was associated with
both increased bleeding and thromboembolic events, espe-
cially in the nonparoxysmal AF [83]. Other observational
studies with a more interrupted approach showed equivalent
bleeding and embolic events compared to therapeutic war-
farin [84–87].
For rivaroxaban, uninterrupted rivaroxaban appears to
be a feasible and safe alternative to uninterrupted warfarin
therapy in patients undergoingAF ablation. Future larger and
randomized trials are needed to confirm those preliminary
data [83].
6. Management in an Emergency Situation
In case of a surgery or invasive procedure, the degree of emer-
gency should be assessed in order to decrease the bleeding
Table 8: Essential prerequisites allowing perioperative decisions.
Molecule
Type
Dose
Indication
Patient
Thromboembolic risk—bleeding risk
Renal function (CrCl—Cockroft and Gault formula)
Hepatic function
Concomitant drugs
Approved NOAC’s indication
Procedure
Type and technique
Bleeding risk
Date of its achievement (Day 0)
Anesthesia General and/or regional (neuroaxial or peripheralnerve blocks)
risk: NOACs must be discontinued, timing of the last dose
intake should be known, and if possible, invasive procedure
should be delayed until the NOACs reach trough concentra-
tion. Waiting and postponing semiurgent procedures may be
a reasonable strategy to prevent bleeding. In case of bleeding
emergencies under NOACs, several difficulties are encoun-
tered: there is currently no antidote and no rapid quantitative
measurement of the anticoagulant effect (see laboratory
testing for NOACs in a perioperative setting), strategies to
reverse the anticoagulant effect are poor, and, depending on
the residual concentration of NOACs, administration of
factors is rendered ineffective [15, 63].
It is very important to establish a hospital-wide policy for
bleeding management in patients taking NOACs, based on
the available blood products and laboratory assays in each
institution. The procedure must be easily accessible (e.g.,
intranet site, personal digital assistant (PDA)). Some work-
groups propose algorithms based onNOAC’s plasma concen-
tration, but their quantitativemeasurements are not currently
routinely performed [88].
In case of bleeding that does not respond to supportive
measures (surgical hemostasis, embolization, fluid replace-
ment, etc.) in patients taking DE, ensure adequate diuresis
and suggest hemodialysis. Dabigatran is 35% bound to
plasma proteins, theoretically allowing its elimination by
hemodialysis, but clinical experience is limited [89–91]. How-
ever, hemodialysis might be more effective than unspecific
reversal treatment with factor concentrates. A single-center
study including patients with end-stage renal disease mea-
sured DE elimination with hemodialysis. Four hours of
hemodialysis with 200mL/min and 400mL/min targeted
blood flow removed 48.8% and 59.3%of total dabigatran from
the central compartment, respectively. There was a linear
relation between anticoagulant activity of dabigatran and
its plasma levels. Minor redistribution of dabigatran (<16%)
after the end of the hemodialysis session occurred. These
results support hemodialysis as a suitable approach to elim-
inate dabigatran in emergency situations [92]. An extracor-
poreal renal replacement therapy filter can also be easily
added during emergent cardiac surgery [93]. However, a
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Table 9: Coagulation factor and pro-hemostatic agents.
Concentrate of factors (II, (VII), IX et X): prothrombin complex
concentrate, PCC, PPSB (Cofact, Confidex, Octaplex, Beriplex) 25U/kg, once or two times
∗
Concentrate of activated factors: idem PCC + VIIa, FEIBA,
(FEIBA) 50 IE/kg, max 200 IE/kg/day
∗
Factor VIIa: (Novoseven) Needs further evaluation: 90𝜇g/kg
Antifibrinolytics (Tranexamic acid (Exacyl), Aminocaproı¨c acid),
Desmopressin (Minirin) No clinical data in this context
Fresh Frozen Plasma (FFP) Not useful to reverse anticoagulation, expand plasma volume incase of massive transfusion
Protamin, vitamin K No effect in case of NOACs bleeding
∗PCC or aPCC utilization is based of few experimental data, can be considered if immediate hemostatic support is essential in case of life-threating bleeding
(need for ≥4 red cells transfusions and exogenous cathecolamins for hemodynamic stabilization).
special care to bleeding at the punctures sites is necessary
and therefore ultrasound guided techniques are very useful.
Hemoperfusion over a charcoal filter is under evaluation [89].
Oral activated charcoal may be effective only in case of a
recent ingestion within 2 hours [89].
An analysis of major bleeding patients in the RE-LY
study concludes that the overall resources required tomanage
bleeding were not greater than those after warfarin-related
bleeding. For patients treated with DE, red cells transfusions
were higher, plasma transfusions were lower, the stay in
intensive care unit was shorter, and there was a lower trend in
mortality compared with patients treated with warfarin.
Based on these results, they concluded on a safety profile of
DE [94].
There is currently no specific hemostatic agent for the
reversal of NOACs in case of bleeding or in emergency situa-
tions but different antidotes are under development. Andex-
anet alfa (PRT064445) is a truncated form of enzymatically
inactive FXa: it reverses dose-dependently the inhibitory
activity and corrects ex vivo clotting times [95]. For dabi-
gatran, a humanized selective and specific monoclonal anti-
body fragment (idarucizumab) is under development [96].
Aripazine (PER977), another small synthetic molecule,
reverses anticoagulant activity of all clinically used NOACs
in rat bleeding models [97].
Hemostatic agents used for life-threatening bleeding are
shown in Table 9.
7. Laboratory Testing for NOACs in
a Perioperative Setting
NOACs do not require routine coagulation monitoring. This
point is considered as an advantage for the physicians and
an improvement of quality of life for their patients. However,
point measurement of NOACs may be required in several
clinical situations including the perioperative setting [8, 10,
11, 78, 98, 99].
For VKAs, it is well established that, at time of surgery
(INR on the day before surgery), an elevated INR (i.e., ≥2)
will increase the risk of bleeding and a near normal or normal
INR (i.e., ≤1.5) will not [60]. But, for NOACs, the residual
drug level that can be considered as safe is not known, except
for dabigatran. The residual dabigatran concentration that is
recommended before special intervention (such as surgery) is
provided in the Committee for Medicinal Products for
Human Use (CHMP) assessment report from the European
Medicine Agency that states “(. . .) dabigatran concentration
under 48 ng/mL is equivalent to at least 75% of dabigatran’s
elimination and should be recommended” [100]. A French
group of experts called GIHP proposed the threshold of
30 ng/mL (for dabigatran and rivaroxaban) [88].
Details of these recommendations are presented in
Table 10 [88].
7.1.Which Laboratory Tests ShouldWeUse in the Perioperative
Setting and How to Interpret Them? Activated partial throm-
boplastin time (aPTT) and prothrombin time (PT) are global
assays not reflecting plasmaNOACs concentrations.They are
not suitable for precise quantification of the anticoagulant
effect. Thrombin time (TT) was demonstrated to be too
sensitive towards dabigatran [89, 101]. However, this may
guide the clinician in the perioperative setting since a nor-
mal TT indicates no clinically relevant anticoagulant effect
of dabigatran.The strong sensitivity of TT towards dabigatran
leads to the development of a calibrated diluted thrombin
time (dTT) with dabigatran standards to calculate the dabi-
gatran plasma concentration. Several studies showed that the
dTT or the ecarin chromogenic assay (ECA) highly correlates
with dabigatran plasma concentrations measured by LC-
MS/MS in patient’s plasma [102–104]. However, one limita-
tion of dTT is that, in case of switching therapy (i.e., from
heparins/heparinoids to dabigatran etexilate or from hirudin
and derivatives to dabigatran etexilate), they will be slightly
influenced by the presence of such inhibitors in the plasma.
This implies the necessity of an accurate anamnesis of the
drugs taken by the patient to avoid overestimation of drug
concentrations in plasma. In addition, for the accurate
determination of dabigatran plasma concentrations below
50 ng/mL, the more sensitive liquid chromatography-mass
spectrometry/mass spectrometry (LC-MS/MS) method is
still required [102, 104].
For rivaroxaban, chromogenic anti-Xa assay has been
proven to accurately estimate the plasma rivaroxaban con-
centrations > 30 ng/mL [105]. Due to their good sensitivity
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Table 10: Perioperative management of NOACs (dabigatran and rivaroxaban)—Proposal for recommendations from the GIHP (“Groupe
d’Inte´reˆt en He´mostase Pe´riope´ratoire”).
Measured concentration Recommendations
<30 ng/mL Operate
30–200 ng/mL Wait up to 12 h and obtain new dosage or (if time is not compatible with emergency)Operate, if abnormal bleeding: antagonise the anticoagulant effect
200–400 ng/mL
Wait up to 12 h and obtain new dosage or (if time is not compatible with emergency)
Maximise delay surgery
Discuss hemodialysis, especially if CrCl < 50mL/min (with dabigatran only)
Operate, if abnormal bleeding: antagonise
>400 ng/mL Overdose-Major haemorrhagic riskDiscuss haemodialysis before surgery (with dabigatran only)
Table 11: Influence of dabigatran, rivaroxaban and apixaban on coagulation tests used in the perioperative setting.
Dabigatran Rivaroxaban Apixaban
Prothrombin Time (PT) Time prolonged + (relative toreagent sensitivity)
Time prolonged + to +++
(relative to reagent sensitivity)
Time non-prolonged or
prolonged + (relative to reagent
sensitivity)
Activated Partial
Thromboplastin Time (aPTT)
Time prolonged + to +++
(relative to reagent sensitivity)
Time prolonged + (relative to
reagent sensitivity)
Time prolonged + (relative to
reagent sensitivity)
PT-based coagulation factors
measurement
(II, VII, IX, X)
Slightly decreased (depending on
the reagent)
Slightly decreased (depending on
the reagent)
Slightly decreased (depending on
the reagent)
APTT-based coagulation
factors measurement
(VIII, IX, XI)
Slightly decreased (depending on
the reagent)
Slightly decreased (depending on
the reagent)
Slightly decreased (depending on
the reagent)
Fibrinogen No influence or slightly decrease(depending on the reagent) No influence No influence
Thrombin Time Time prolonged +++++ No influence No influence
Anti-Xa based antithrombin
measurement No influence Increased: 10% per 100 ng/mL Increased: 10% per 100 ng/mL
Anti-IIa based antithrombin
measurement Increased: 5–10% per 100 ng/mL No influence No influence
towards the inhibition of FXa by apixaban, chromogenic
anti-Xa assays calibrated with specific apixaban calibrators
should be performed to estimate plasma drug concentration
[106–108]. However, taking into account the lower sensitivity
of chromogenic assays compared to LC-MS/MS and the
variability of coagulation analysers that may further increase
the imprecision at the lowest concentrations, detection and
quantitation of lower levels (<30 ng/mL for rivaroxaban and
<15 ng/mL for apixaban) still require LC-MS/MS analyses
[108, 109].
Even if these specific coagulation tests to assess NOACs
are promising, they suffer fromdifficulties to be implemented
easily in the clinical setting. Moreover, assessment of lower
levels of NOACs encountered in the perioperative setting is
challenging due to the limit of quantitation of these tests but
improvements in the low range are under development by
several companies.
In addition, to correctly interpret the results of laboratory
assay, some information needs to be collected: drug, indi-
cation, and the timing of the last dose administration (due
to the short half-life of NOACs) [110]. The interpretation of
the results requires education of the front staff in many
specialties [98]. Finally, it has been clearly shown thatNOACs
influence the results of different coagulation assays used in
the perioperative setting leading to misinterpretations [41]
(Table 11).
7.2. A Particular Case: Atrial Fibrillation Ablation. The ideal
management of oral anticoagulation during catheter ablation
for AF 112–114 is still controversial with a wide range of proce-
dures available. During AF ablation, it is now recommended
to achieve and maintain an ACT of 300 to 400 seconds in
order to reduce the risk of systemic thromboembolism [111].
However, the ACT is affected by a lot of preanalytical [112]
and analytical variables [113, 114]. Finally, target ACT should
be redetermined for the periprocedural use of NOACs for AF
ablation [111–117].
8. Resumption of the NOACs after
Invasive Procedure or Surgery
Once again, in the postoperative period, the bleeding risk
must be weightedwith the thromboembolic risk; however the
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risk for major bleeding exceeds the risk for thromboembolic
complications after surgery [118]. Regarding the thromboem-
bolic risk, Kaatz et al. [119] concluded that patients with
chronic AF had twice as much risks of postoperative stroke,
especially in neurosurgery and vascular surgery.The bleeding
risk in the postoperative period is mainly due to patient’s
characteristics (bridging therapy, mitral mechanic heart
valve, active cancer, prior bleeding history, and reinitiation
of heparin therapy within 24 hours after surgery), even if
a premature heparin resumption is an avoidable risk factor
[120]. But first of all surgical bleeding risk must be under
control [121]. For NOACs, given the fact that full antico-
agulation occurs between 2 and 4 hours (Table 3) and that
no antidote is available, resumption of DE, rivaroxaban, and
apixaban should be performed at least 48 hours after the high
risk procedures [12]. This delay can expose patients at risk
for thromboembolism. Twenty-four hours are recommended
before resuming oral anticoagulation after a procedure at low
risk of bleeding [60, 62]. Other schemes exist in order to
minimize bleeding risks: consider a stepwise resumption of
NOACs [16, 77] or administer prophylactic doses of LMWH
early after the surgery, and restart full doses of NOACs
only after 3 or 4 days [122]. Heparin bridging can be useful
if the patient cannot tolerate oral medication (e.g., in ileus or
postoperative nausea and vomiting) [66]. In the postopera-
tive setting, it is essential to reassess patient’s renal function,
especially for elderly who are subject to dehydration and
for patients taking DE. For LMWH, doses must be adapted
in case of extreme body weight (body mass index above
30 kg/m2) and poor renal function. If CrCl is less than
30mL/min, the use of unfractionated heparin is more indi-
cated [12, 123].
9. Conclusions
In the field of oral anticoagulation, clinicians will be more
frequently confronted about their management of NOACs
in the pre- and postoperative setting. Prerequisites are
essential for NOAC’s pharmacokinetics, indications, drug
interactions, and alterations of standard laboratory assays.
Actual data are based mainly on expert’s opinions, except
one national registry study. In some situation, interruption
periods of NOACs are necessary and should be based on their
respective half-life, on the bleeding risk of procedures, and on
the thromboembolic risk of patients. Some scores such as
CHA
2
DS
2
-VASc and HAS-BLED should help clinicians in
their decisions. Given their shorter half-life, no heparin
bridging during the interruption interval seems necessary,
except for patients at high cardiovascular risk undergoing
major surgery.
Further clinical trials over perioperative management of
patients under NOACs are still required. Emergency surg-
eries, invasive procedures, or bleeding patients remain a real
challenge given the absence of antidote. Possibilities of rever-
sal are poor and based on few experimental data and case
reports. Furthermore, rapid quantitativemeasurements of the
anticoagulant effect are not available in most institutions.
Awaiting future clinical trial data, it seems to be important to
establish a hospital-wide policy for bleeding management in
patients taking NOACs, in accordance to the available blood
products and laboratory assays of each institution.
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